Brivaracetam in epilepsy: A mini-review of the literature
Volume 5 - Issue 3
Maria Stefanatou*
- 1st Department of Neurology, National and Kapodistrian University of Athens, Athens, Greece
Received: March 8, 2021 Published:March 17, 2021
Corresponding author: Maria Stefanatou, 1st Department of Neurology, National and Kapodistrian University of Athens, Athens, Greece
DOI: 10.32474/OJNBD.2021.05.000214
Fulltext
PDF
To view the Full Article Peer-reviewed Article PDF
Brivaracetam (BRV) is the latest approved antiepileptic drug and acts as a high-affinity Synaptic Vesicle protein2A (SV2A) ligand
that exceeds the binding potential of Levetiracetam (LEV). In the European Union, BRV is only approved as an adjunctive therapy
for the treatment of Partial-Onset Seizures (POS) with or without secondary generalization, in patients 4 years of age and older
with epilepsy, while F.D.A. has recently approved its use as monotherapy in partial-onset seizures in adults. In Phase III clinical
trials, BRV has shown efficacy and an adequate safety profile in patients suffering from POS. In additional open-label studies, BRV
has demonstrated satisfying results and high retention rates in patients with both focal – onset and genetic generalized epilepsies.
The main Treatment-Emergent Adverse Events (TEAEs) observed during the regulatory and open label trials were somnolence,
dizziness and headache following by fatigue and nausea. Brivaracetam seems to be an effective, easy to use and safe antiepileptic
drug in clinical setting.
Abstract|
Introduction|
Brivaracetam|
Conclusion|
References|